Additionally, CAIX-targeted immune therapies, such as autologous DCs transduced with a granulocyte–macrophage colony-stimulating factor/CAIX fusion construct (DC-AdGMCAIX), have shown a CAIX-specific immune response in Phase I trials for renal cancer (ClinicalTrials.gov Identifier: NCT01826877), underscoring the potential of CAIX-targeted approaches [286]. Here, CA9 is linked to renal carcinoma.